Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

被引：23
作者：
Othus, M. [1 ]
Mukherjee, S. [2 ]
Sekeres, M. A. [2 ]
Godwin, J. [3 ]
Petersdorf, S. [4 ]
Appelbaum, F. R. [1 ]
Erba, H. [5 ]
Estey, E. [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[2] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH USA
[3] Earle A Chiles Res Inst, Providence Canc Ctr, Portland, OR USA
[4] Seattle Genet, Seattle, WA USA
[5] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
来源：
LEUKEMIA | 2016年 / 30卷 / 08期
关键词：
SOUTHWEST-ONCOLOGY-GROUP; INDUCTION CHEMOTHERAPY; THERAPY; TRIAL; DAUNORUBICIN; CYTARABINE;
D O I：
10.1038/leu.2016.48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1779 / 1780
页数：2
相关论文
共 8 条
[1]   Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study [J].
Anderson, JE ;
Kopecky, KJ ;
Willman, CL ;
Head, D ;
O'Donnell, MR ;
Luthardt, FW ;
Norwood, TH ;
Chen, IM ;
Balcerzak, SP ;
Johnson, DB ;
Appelbaum, FR .
BLOOD, 2002, 100 (12) :3869-3876
[2]   An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy [J].
Ferguson, Paul ;
Hills, Robert K. ;
Grech, Angela ;
Betteridge, Sophie ;
Kjeldsen, Lars ;
Dennis, Michael ;
Vyas, Paresh ;
Burnett, Alan K. ;
Goldstone, Anthony H. ;
Milligan, Donald ;
Clark, Richard E. ;
Russell, Nigel H. ;
Craddock, Charles .
BLOOD, 2015, 126 (23)
[3]   A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031) [J].
Godwin, JE ;
Kopecky, KJ ;
Head, DR ;
Willman, CL ;
Leith, CP ;
Hynes, HE ;
Balcerzak, SP ;
Appelbaum, FR .
BLOOD, 1998, 91 (10) :3607-3615
[4]   Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia:: data from the German AML Cooperative Group (AMLCG) 1992 Trial [J].
Kern, W ;
Haferlach, T ;
Schoch, C ;
Löffler, H ;
Gassmann, W ;
Heinecke, A ;
Sauerland, MC ;
Berdel, W ;
Büchner, T ;
Hiddemann, W .
BLOOD, 2003, 101 (01) :64-70
[5]   A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia [J].
Petersdorf, Stephen H. ;
Kopecky, Kenneth J. ;
Slovak, Marilyn ;
Willman, Cheryl ;
Nevill, Thomas ;
Brandwein, Joseph ;
Larson, Richard A. ;
Erba, Harry P. ;
Stiff, Patrick J. ;
Stuart, Robert K. ;
Walter, Roland B. ;
Tallman, Martin S. ;
Stenke, Leif ;
Appelbaum, Frederick R. .
BLOOD, 2013, 121 (24) :4854-4860
[6]   Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy [J].
Ravandi, Farhad ;
Cortes, Jorge ;
Faderl, Stefan ;
O'Brien, Susan ;
Garcia-Manero, Guillermo ;
Verstovsek, Srdan ;
Santos, Fabio P. S. ;
Shan, Jianqin ;
Brandt, Mark ;
de Lima, Marcos ;
Pierce, Sherry ;
Kantarjian, Hagop .
BLOOD, 2010, 116 (26) :5818-5823
[7]   A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study [J].
Weick, JK ;
Kopecky, KJ ;
Appelbaum, FR ;
Head, DR ;
Kingsbury, LL ;
Balcerzak, SP ;
Bickers, JN ;
Hynes, HE ;
Welborn, JL ;
Simon, SR ;
Grever, M .
BLOOD, 1996, 88 (08) :2841-2851
[8]   A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial [J].
Wheatley, K ;
Burnett, AK ;
Goldstone, AH ;
Gray, RG ;
Hann, IM ;
Harrison, CJ ;
Rees, JKH ;
Stevens, RF ;
Walker, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :69-79
1